Premium
Factor VIII inhibitor bypassing activity (FEIBA) – addressing safety issues
Author(s) -
ALEDORT L. M.
Publication year - 2008
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2007.01594.x
Subject(s) - medicine , tolerability , haemophilia , anamnesis , intensive care medicine , clinical trial , adverse effect , surgery
Summary. Bypassing therapy is usually necessary to control or prevent bleeding episodes in patients with haemophilia A or B and high‐titre inhibitors. Factor VIII inhibitor bypassing activity (FEIBA) has a long history of successful use in the acute, surgical and prophylactic treatment settings, but safety concerns have made some reluctant to administer this bypassing agent. A review of the literature and clinical trial data show that FEIBA has a low prevalence of thrombosis, a low prevalence of anamnesis that does not impact haemostatic efficacy and an excellent record of pathogen safety and clinical tolerability.